We are live on
!
Find out more
RG
Redmile Group Portfolio holdings
AUM
$1.51B
1-Year Est. Return
164.17%
This Fund
S&P 500
This Quarter
Est. Return
+22.9%
1 Year Est. Return
+164.17%
3 Year Est. Return
+929.47%
5 Year Est. Return
+823.75%
10 Year Est. Return
+18,826.17%
AUM
$1.54B
AUM Growth
+$381M
(+33%)
Cap. Flow
+$151M
Cap. Flow
% of AUM
9.83%
Top 10 Holdings %
Top 10 Hldgs %
42.85%
Holding
66
New
16
Increased
21
Reduced
18
Closed
6
Top Buys
| 1 |
SYNH
Syneos Health, Inc. Class A Common Stock
SYNH
|
+$31.5M |
| 2 |
Neurocrine Biosciences
NBIX
|
+$26.7M |
| 3 |
Regenxbio
RGNX
|
+$24.5M |
| 4 |
JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
|
+$23.6M |
| 5 |
ICU Medical
ICUI
|
+$23.5M |
Top Sells
| 1 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$51.5M |
| 2 |
ARIA
Ariad Pharmaceuticals Inc
ARIA
|
+$47.7M |
| 3 |
ARRY
Array Biopharma Inc
ARRY
|
+$41M |
| 4 |
CLVS
Clovis Oncology, Inc.
CLVS
|
+$39.4M |
| 5 |
Centene
CNC
|
+$29.2M |
Sector Composition
| 1 | Healthcare | 93.1% |
| 2 | Financials | 0.93% |
| 3 | Communication Services | 0.56% |
| 4 | Technology | 0% |
| 5 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
JNCE
26
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
| $22.5M | 1.46% |
+1,114,160
| New | +$23.6M |
|
|
IMMU
27
DELISTED
Immunomedics Inc
IMMU
| $21.9M | 1.42% |
+3,380,846
| New | +$17.1M |
|
|
PTHN
28
DELISTED
Patheon N.V.
PTHN
| $21.8M | 1.41% |
826,843
+386,123
| +88% | +$11.3M |
|
|
DPLO
29
DELISTED
DIPLOMAT PHARMACY, INC.
DPLO
| $20M | 1.3% |
1,254,342
+1,101,025
| +718% | +$15.9M |
|
|
ELGX
30
DELISTED
Endologix Inc
ELGX
| $19.7M | 1.28% |
271,739
+151,050
| +125% | +$9.99M |
|
|
ESRX
31
DELISTED
Express Scripts Holding Company
ESRX
| $19.4M | 1.26% |
293,807
-44,993
| -13% | -$3.1M |
|
|
NSTG
32
DELISTED
NanoString Technologies, Inc.
NSTG
| $18.6M | 1.21% |
934,424
-3,533
| -0.4% | -$67.2K |
|
|
LJPC
33
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $18M | 1.17% |
+604,470
| New | +$15.4M |
|
|
CTLT
34
DELISTED
CATALENT, INC.
CTLT
| $17.7M | 1.15% |
+624,000
| New | +$17.5M |
|
|
CASC
35
DELISTED
Cascadian Therapeutics, Inc.
CASC
| $16.9M | 1.09% |
+4,072,424
| New | +$17.1M |
|
|
PRXL
36
DELISTED
Parexel International Corp
PRXL
| $16.4M | 1.07% |
+260,231
| New | +$17.2M |
|
|
SPNC
37
DELISTED
Spectranetics Corp
SPNC
| $16.2M | 1.05% |
557,189
+369,562
| +197% | +$9.85M |
|
|
BPMC
38
DELISTED
Blueprint Medicines
BPMC
| $16M | 1.04% |
+400,000
| New | +$14.3M |
|
|
IMGN
39
DELISTED
Immunogen Inc
IMGN
| $15.4M | 1% |
+3,984,734
| New | +$11.6M |
|
|
SYRS
40
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $15.2M | 0.99% |
95,274
+430
| +0.5% | +$52.5K |
|
41
eHealth
EHTH
$48.6M
| $14.3M | 0.93% |
1,191,334
+193,713
| +19% | +$2.24M |
|
|
BOLD
42
DELISTED
Audentes Therapeutics, Inc
BOLD
| $14M | 0.91% |
820,836
-11,900
| -1% | -$192K |
|
43
CytomX Therapeutics
CTMX
$801M
| $11.8M | 0.76% |
681,892
-15,100
| -2% | -$199K |
|
44
McKesson
MCK
$93.2B
| $11.6M | 0.75% |
+78,300
| New | +$11.5M |
|
45
Charles River Laboratories
CRL
$11B
| $10.9M | 0.71% |
121,307
-125,800
| -51% | -$10.7M |
|
|
NVTA
46
DELISTED
Invitae Corporation
NVTA
| $8.98M | 0.58% |
812,240
-252,762
| -24% | -$2.42M |
|
|
MODN
47
DELISTED
MODEL N, INC.
MODN
| $8.59M | 0.56% |
822,314
+12,400
| +2% | +$121K |
|
48
ProQR Therapeutics
PRQR
$250M
| $7.77M | 0.5% |
1,553,225
-24,949
| -2% | -$110K |
|
49
Fate Therapeutics
FATE
$349M
| $6.46M | 0.42% |
1,419,058
| – | – |
|
|
DVAX
50
DELISTED
Dynavax Technologies
DVAX
| $6.07M | 0.39% |
1,019,491
-30,300
| -3% | -$146K |
|
Similar funds
ORI
GAI
HCMG
FMI
FCM
PP
AM
BFO